| scholarly article | Q13442814 |
| P50 | author | Nicolas Bonnet | Q51535115 |
| P2093 | author name string | Dominique D Pierroz | |
| Serge L Ferrari | |||
| Michael S Ominsky | |||
| Paul J Kostenuik | |||
| Paul A Baldock | |||
| Marina Stolina | |||
| P2860 | cites work | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification | Q24603266 | ||
| Giant osteoclast formation and long-term oral bisphosphonate therapy | Q24626459 | ||
| Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Cellular and molecular mechanisms of action of bisphosphonates | Q33970504 | ||
| Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. | Q33995702 | ||
| EphrinB2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts | Q34796085 | ||
| beta-Arrestin2 regulates the differential response of cortical and trabecular bone to intermittent PTH in female mice | Q35062148 | ||
| Osteoclast-derived activity in the coupling of bone formation to resorption. | Q36032429 | ||
| Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength | Q36269835 | ||
| Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis | Q36368706 | ||
| Mechanisms involved in skeletal anabolic therapies. | Q36532582 | ||
| The use of parathyroid hormone in the treatment of osteoporosis | Q36624534 | ||
| RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism | Q37108966 | ||
| Beta-Arrestin2 regulates RANKL and ephrins gene expression in response to bone remodeling in mice. | Q37166800 | ||
| Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor | Q37197357 | ||
| Parathyroid hormone treatment for osteoporosis | Q37312941 | ||
| Local communication on and within bone controls bone remodeling. | Q37433014 | ||
| Hypothalamic control of bone formation: distinct actions of leptin and y2 receptor pathways | Q38321099 | ||
| Basic biomechanical measurements of bone: a tutorial | Q40797364 | ||
| The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis | Q44590934 | ||
| The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis | Q44590937 | ||
| OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats | Q46099755 | ||
| One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strength | Q46171552 | ||
| RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats | Q46212098 | ||
| Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial | Q46393065 | ||
| Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. | Q46459616 | ||
| Daily and cyclic parathyroid hormone in women receiving alendronate | Q46644473 | ||
| A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide | Q46954772 | ||
| Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity | Q47988162 | ||
| The effects of combination of alendronate and human parathyroid hormone(1-34) on bone strength are synergistic in the lumbar vertebra and additive in the femur of C57BL/6J mice. | Q51750185 | ||
| Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis | Q57675131 | ||
| Trabecular and endocortical bone surfaces in the rat: modeling or remodeling? | Q71697391 | ||
| Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: evidence for de novo bone formation on quiescent cancellous surfaces | Q72908534 | ||
| On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism | Q77738452 | ||
| Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice | Q79171394 | ||
| Pretreatment with anticatabolic agents blunts but does not eliminate the skeletal anabolic response to parathyroid hormone in oophorectomized mice | Q80018761 | ||
| Effects of daily treatment with parathyroid hormone 1-84 for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys | Q80487618 | ||
| Mechanisms of the anabolic effects of teriparatide on bone: insight from the treatment of a patient with pycnodysostosis | Q80779491 | ||
| Bone response to intermittent parathyroid hormone is altered in mice null for {beta}-Arrestin2 | Q81391001 | ||
| Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis | Q83924332 | ||
| P433 | issue | 36 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 28164-28173 | |
| P577 | publication date | 2010-06-17 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL | |
| P478 | volume | 285 |
| Q46907891 | A Novel, Direct NO Donor Regulates Osteoblast and Osteoclast Functions and Increases Bone Mass in Ovariectomized Mice |
| Q37679606 | A closer look at the immediate trabecula response to combined parathyroid hormone and alendronate treatment. |
| Q38047183 | Advances in osteoimmunology: pathophysiologic concepts and treatment opportunities |
| Q44216694 | An experimental therapy to improve skeletal growth and prevent bone loss in a mouse model overexpressing IL-6. |
| Q37673469 | Bone biology and anabolic therapies for bone: current status and future prospects |
| Q27025688 | Bone health and associated metabolic complications in neuromuscular diseases |
| Q36524611 | Denosumab-associated osteonecrosis of the jaw affects osteoclast formation and differentiation: Pathological features of two cases |
| Q91768602 | Effect of parathyroid hormone on the structural, densitometric and failure behaviors of mouse tibia in the spatiotemporal space |
| Q46583319 | Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis |
| Q34182919 | Emerging therapies in metastatic bone pain |
| Q37370284 | Enhanced individual trabecular repair and its mechanical implications in parathyroid hormone and alendronate treated rat tibial bone. |
| Q38661460 | Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells |
| Q38183262 | Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib. |
| Q35378487 | Increased bone mass in mice after single injection of anti-receptor activator of nuclear factor-kappaB ligand-neutralizing antibody: evidence for bone anabolic effect of parathyroid hormone in mice with few osteoclasts |
| Q37720404 | Individual and combining effects of anti-RANKL monoclonal antibody and teriparatide in ovariectomized mice |
| Q36647074 | Intermittent PTH administration and mechanical loading are anabolic for periprosthetic cancellous bone. |
| Q46977608 | Is it time to combine osteoporosis therapies? |
| Q26741146 | Longitudinal imaging of the ageing mouse |
| Q37414413 | Mechanisms of osteoclast-dependent bone formation |
| Q64081065 | Molecular understanding of pharmacological treatment of osteoporosis |
| Q37110385 | Monocyte chemoattractant protein-1 is a mediator of the anabolic action of parathyroid hormone on bone. |
| Q38205860 | Novel techniques in the development of osteoporosis drug therapy: the osteoclast ruffled-border vacuolar H(+)-ATPase as an emerging target |
| Q39283452 | One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption |
| Q33993757 | Osteoclasts: more than 'bone eaters'. |
| Q38230277 | Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles? |
| Q38257484 | Osteoporosis therapy: a novel insight from natural homeostatic system in the skeleton |
| Q51703751 | Overexpression of Gα11 in Osteoblast Lineage Cells Suppresses the Osteoanabolic Response to Intermittent PTH and Exercise. |
| Q37661167 | Parathyroid Hormone (1-34) Might Not Improve Early Bone Healing after Sinus Augmentation in Healthy Rabbits. |
| Q57217564 | Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis |
| Q57976931 | Pharmacological inhibition of Dock5 prevents osteolysis by affecting osteoclast podosome organization while preserving bone formation |
| Q48986728 | Pharmacologically Inactive Bisphosphonates as an Alternative Strategy for Targeting Osteoclasts: In Vivo Assessment of 5-Fluorodeoxyuridine-Alendronate in a Preclinical Model of Breast Cancer Bone Metastases |
| Q54228752 | RANKL blockade prevents and treats aggressive osteosarcomas. |
| Q36236285 | Regulation of beta catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin |
| Q37385579 | Release of bone markers in immediately loaded and nonloaded dental implants: a randomized clinical trial |
| Q30455154 | Role of denosumab in prostate cancer |
| Q34551704 | Soluble guanylate cyclase as a novel treatment target for osteoporosis |
| Q54229745 | Suppression of p38α MAPK Signaling in Osteoblast Lineage Cells Impairs Bone Anabolic Action of Parathyroid Hormone. |
| Q35165694 | Teriparatide Therapy as an Adjuvant for Tissue Engineering and Integration of Biomaterials |
| Q30627873 | Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. |
| Q46851946 | The effect of etidronate on the periodontium of ovariectomized rats |
| Q34079954 | The effects of PTH, loading and surgical insult on cancellous bone at the bone-implant interface in the rabbit. |
| Q41989650 | The inhibitory effects of a RANKL-binding peptide on articular and periarticular bone loss in a murine model of collagen-induced arthritis: a bone histomorphometric study. |
| Q38827517 | The skeletal impact of the chemotherapeutic agent etoposide |
| Q39324421 | Three-dimensional image registration improves the long-term precision of in vivo micro-computed tomographic measurements in anabolic and catabolic mouse models |
| Q35108947 | μCT-based, in vivo dynamic bone histomorphometry allows 3D evaluation of the early responses of bone resorption and formation to PTH and alendronate combination therapy |
Search more.